Tech Company Financing Transactions
Cabaletta Bio Funding Round
Cabaletta Bio, based in Philadelphia, secured $50 million from 5AM Ventures, Adage Capital Management and Boxer Capital.
Transaction Overview
Company Name
Announced On
1/4/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will support establishment of translational research and advanced manufacturing capabilities to complement Cabaletta's relationship with the Center for Cellular Immunotherapies in the Abramson Center at the University of Pennsylvania (Penn).
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2929 Arch St. 600
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Website
Email Address
Overview
Cabaletta Bio (Nasdaq: CABA) is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Nichtberger
Chief Financial Officer
Anup Marda
Chief Marketing Officer
David Chang
Chief Technical Officer
Gwendolyn Binder
VP - Bus. Development
Arun Das
Browse more venture capital transactions:
Prev: 1/4/2019: Tiburio Therapeutics venture capital transaction
Next: 1/4/2019: Ablative Solutions venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs